We are pleased to announce the publication of our research paper exploring the impact of SARS-CoV-2 infection on clinically relevant drug processing proteins, including drug metabolizing enzymes and membrane transporters. Our findings shed light on the potential implications of this viral infection in modulating interindividual variations in drug response.
Our study investigated the effect of SARS-CoV-2 infection on the expression of key drug processing proteins and their potential impact on drug efficacy and toxicity. Through rigorous experimentation and data analysis, we have identified significant changes in the expression of these proteins, which may have a profound impact on drug metabolism and transport, as well as overall patient outcomes.
Our research provides a critical insight into the complex interplay between viral infection and drug response, offering important implications for the development of personalized medicine and the optimization of drug therapies. We are confident that our findings will serve as a valuable resource for the scientific community and inspire further research in this important field.
Frontiers | SARS-CoV-2 infection dysregulates the expression of clinically relevant drug metabolizing enzymes in Vero E6 cells and membrane transporters in human lung tissues (frontiersin.org)
#covid19research #Pharmacotherapy #pharmacogenomics #pharmacology
------------------------------
Chukwunonso Nwabufo
Senior Research Associate I,
Analytical Operations,
Gilead Sciences Alberta Canada
Edmonton AB
[email protected]Disclaimer: Opinions expressed are solely my own and do not express the views or opinions of my employer.
------------------------------